WINNIPEG, Manitoba – February 26, 2026
Emergent BioSolutions (NYSE: EBS) has announced approximately $140 million CAD in multiyear contract awards from the Public Health Agency of Canada (PHAC) and the Department of National Defence (DND) to supply critical medical countermeasures supporting Canada’s biological threat preparedness infrastructure.
The agreements reinforce more than a decade of collaboration between Emergent and Canadian authorities and strengthen national capabilities in biodefense manufacturing, strategic stockpiling, and health security resilience. The company expects to receive more than $35 million CAD in orders in 2026 alone, reflecting immediate procurement activity under the expanded contracts
Multiyear Contracts Bolster National Health Security
Under the agreements, Emergent will deliver four medical countermeasures designed to protect against or treat biological threats, ensuring continuous access to essential therapeutics and surge manufacturing capacity if required. The committed annual procurements provide supply chain predictability while enabling rapid scaling in the event of emerging biological risks. Several of these countermeasures are manufactured at Emergent’s Health Canada–licensed facility, reinforcing domestic production capacity and reducing reliance on external supply chains. This localized manufacturing approach aligns with Canada’s evolving Defence Industrial Strategy, which identifies medical countermeasures as a sovereign capability critical to national preparedness.
The contracts illustrate a coordinated strategy between defense and public health agencies to strengthen Canada’s readiness posture. By investing in long-term procurement agreements, Canadian authorities aim to ensure that essential biodefense assets remain available, compliant with regulatory standards, and deployable during public health emergencies.
Advertisement
Innovative Supply Model Enhances Preparedness
Emergent’s manufacturing framework incorporates an innovative rolling production model, in which drug substance is produced continuously and converted annually into finished drug product. This model supports secure supply chains, improved inventory management, and faster deployment during crisis scenarios. Rather than relying on reactive production during outbreaks, the system maintains readiness through proactive stockpile management, enhancing operational agility.
The approach also strengthens biomanufacturing workforce stability and regulatory oversight, as facilities operate on a consistent production cadence rather than intermittent emergency activation. Such preparedness models are increasingly viewed as essential in a global environment characterized by evolving biological threats, emerging infectious diseases, and geopolitical instability.
Public-Private Collaboration in Biodefense
Canadian defense and public health leaders emphasized that health security is a pillar of national security, requiring vigilance and strategic foresight comparable to traditional defense investments. Emergent’s continued partnership with Canadian authorities demonstrates how public-private collaboration can reinforce national resilience, combining regulatory compliance, manufacturing expertise, and coordinated government planning.
Emergent BioSolutions has more than 25 years of experience developing and supplying countermeasures for threats including smallpox, mpox, botulism, Ebola, anthrax, and opioid overdose emergencies.The expanded Canadian agreements further position the company as a key partner in global biodefense preparedness initiatives.
As governments worldwide reassess strategic health security frameworks, sustained procurement commitments such as these highlight the growing importance of regulated pharmaceutical manufacturing, domestic capacity building, and coordinated biodefense infrastructure. The $140 million CAD investment underscores Canada’s commitment to maintaining robust, compliant, and rapidly deployable medical countermeasure capabilities to protect public health and national sovereignty.
Source: Emergent BioSolutions press release
